Key clinical point: A secondary analysis suggests the presence of somatic mutations in the BCL2 gene may have prognostic significance in patients with diffuse large B-cell lymphoma (DLBCL).
Major finding: In the multivariate analysis, the presence of BCL2 mutations was significantly associated with shorter progression- free survival (hazard ratio: 2.6; 95% CI, 1.6-4.2).
Study details: An integrated analysis of molecular data for 499 patients from the phase 3 GOYA trial.
Disclosures: The study was funded by F. Hoffmann-La Roche. The authors reported having financial affiliations with F. Hoffman-La Roche and other companies.
Bolen CR et al. Haematologica. 2019 Nov 14. doi: 10.3324/haematol.2019.227892.